Cargando…

No Emergent Resistance in HIV-1 Infected Virologically-Suppressed Subjects Who Switched to R/F/TAF

BACKGROUND: GS-US-366-1216 and GS-US-366-1160 are randomized, double-blind, phase 3b studies evaluating the safety and efficacy of switching to rilpivirine/emtricitabine/tenofovir alafenamide (R/F/TAF) from R/F/tenofovir disoproxil fumarate (TDF) or efavirenz (EFV)/F/TDF, respectively, in HIV-1-infe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Porter, Danielle, Kulkarni, Rima, Cao, Huyen, Sengupta, Devi, White, Kirsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630830/ http://dx.doi.org/10.1093/ofid/ofx163.1077

Ejemplares similares

109. Preexisting Resistance and Week 48 Virologic Outcomes After Switching to B/F/TAF in African American Adults with HIV
por: Andreatta, Kristen, et al.
Publicado: (2020)

2508. Virologic Suppression in Patients Switched to BIC/TAF/FTC with Baseline NRTI and/or INSTI Resistance
por: Natali, Kayla M, et al.
Publicado: (2019)

Viral Blips Were Infrequent in HIV-1-Infected Virologically-Suppressed Adults Treated with Tenofovir Alafenamide or Tenofovir DF Rilpivirine-Containing Regimens
por: Wohl, David A, et al.
Publicado: (2017)

A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination
por: Sax, Paul E, et al.
Publicado: (2017)

979. BMI and ASCVD Risk Score Changes in Virologically Suppressed Patients with HIV Switching from TDF to TAF Containing ART
por: Schafer, Jason J, et al.
Publicado: (2019)

828. Short- and Long-Term Metabolic Changes in Virologically Suppressed Patients Switching from TDF to TAF Containing Antiretroviral Therapy
por: Schafer, Jason J, et al.
Publicado: (2021)

1012. Efficacy, safety and tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected virologically-suppressed older adults in a real-world setting
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2020)

1598. Predictive equations for immune recovery at 48 weeks of BIC/FTC/TAF treatment in Virologically Suppressed PLWHIV.
por: Tomé, Roberto Pedrero, et al.
Publicado: (2023)

1571. BIC/FTC/TAF in Virologically Suppressed PLWHIV: 48-96 weeks RETROBIC Multicenter Cohort study results.
por: Estévez, Samuel, et al.
Publicado: (2023)

Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results
por: Daar, Eric, et al.
Publicado: (2017)

A Randomized Clinical Trial of Transgender Women Switching to B/F/TAF: The (mo)BETTA Trial
por: Lake, Jordan E, et al.
Publicado: (2023)

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus
por: Sax, Paul E, et al.
Publicado: (2020)

900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study)
por: Osiyemi, Olayemi, et al.
Publicado: (2021)

Taf2 mediates DNA binding of Taf14
por: Klein, Brianna J., et al.
Publicado: (2022)

633. Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Efficacy in Participants with Pre-Existing Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials
por: D’Antoni, Michelle L, et al.
Publicado: (2020)

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor
por: Fisher, Martin, et al.
Publicado: (2014)

Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
por: Chang, Hui-Min, et al.
Publicado: (2021)

1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis
por: Eron, Joseph J, et al.
Publicado: (2020)

337. Switching from TDF to TAF: Missed Opportunities for Statin Use in HIV
por: Mallon, Patrick, et al.
Publicado: (2019)

1448. Forgiveness of BIC/FTC/TAF: In Vitro Simulations of Intermittent Poor Adherence Find Limited HIV-1 Breakthrough and High Barrier to Resistance
por: Mulato, Andrew, et al.
Publicado: (2020)

Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials
por: Reeves, Iain, et al.
Publicado: (2014)

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
por: Llibre, Josep M, et al.
Publicado: (2014)

Cytoplasmic TAF2–TAF8–TAF10 complex provides evidence for nuclear holo–TFIID assembly from preformed submodules
por: Trowitzsch, Simon, et al.
Publicado: (2015)

Identification of a Small TAF Complex and Its Role in the Assembly of TAF-Containing Complexes
por: Demény, Màté A., et al.
Publicado: (2007)

1466. Antiretroviral (ART) Virologic Suppression (VS) and Patient Reported Outcomes (PROs) at 6 Months in the Clinical Opportunities and Management to Exploit Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) an Asynchronous Connection Key (COMEBACK) Study
por: Roden, Lindsey, et al.
Publicado: (2022)

1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV
por: Hagins, Debbie, et al.
Publicado: (2020)

Weight gain before and after switch from TDF to TAF in a U.S. cohort study
por: Mallon, Patrick WG, et al.
Publicado: (2021)

Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides
por: Mallon, Patrick W G, et al.
Publicado: (2021)

Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains
por: Bouché, Léa, et al.
Publicado: (2017)

1288. Bone Safety Outcomes with F/TAF vs. F/TDF for PrEP in the DISCOVER Trial
por: Wohl, David, et al.
Publicado: (2019)

69. Incidence of metabolic complications among treatment-naïve adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks
por: Daar, Eric, et al.
Publicado: (2021)

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study
por: Giacomelli, Andrea, et al.
Publicado: (2021)

Reduced oxidative stress suppresses neurotoxicity in the Drosophila model of TAF15-associated proteinopathies
por: Han, Yeo Jeong, et al.
Publicado: (2022)

Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
por: Sax, Paul, et al.
Publicado: (2020)

Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study
por: Lee, Chun-Yuan, et al.
Publicado: (2022)

Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
por: Hayes, Edwin, et al.
Publicado: (2020)

Improvement in Hydriding and Dehydriding Features of Mg–TaF(5)–VCl(3) Alloy by Adding Ni and x wt% MgH(2) (x = 1, 5, and 10) Together with TaF(5) and VCl(3)
por: Kwak, Young-Jun, et al.
Publicado: (2021)

1962. Renal Outcomes for Participants Taking F/TAF vs. F/TDF for HIV PrEP in the DISCOVER Trial
por: Mills, Anthony, et al.
Publicado: (2019)

995. Safety and Efficacy of F/TAF and F/TDF for PrEP in DISCOVER Participants Taking F/TDF for PrEP at Baseline
por: Campbell, Thomas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j21ablmupt9mkloj2cea2jaqlq